CABA Earnings & Financial Statements
Cabaletta Bio, Inc.
$1.92
-$0.05(-2.79%)
29
Overall
60
Value
18
Tech
10
Quality
Market Cap
$334.00M
Volume
3.48M
52W Range
$1.83 - $4.23
Target Price
$13.25
CABA earnings and financial statements: Cabaletta Bio, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
CABA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$172.24M | -$125.14M | -$74.66M | -$54.14M | -$46.31M |
| EBITDA | -$164.21M | -$113.41M | -$66.25M | -$52.96M | -$45.58M |
| Net income | -$167.86M | -$115.86M | -$67.67M | -$52.98M | -$46.29M |
| EPS (diluted) | $-2.10 | $-2.34 | $-1.65 | $-1.81 | $-1.80 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $165.08M | $185.05M | $253.65M | $116.97M | $126.34M |
| Total liabilities | $53.03M | $32.71M | $17.45M | $12.45M | $8.38M |
| Shareholders’ equity | $112.05M | $152.34M | $236.20M | $104.52M | $117.96M |
| Cash and equivalents | $82.98M | $163.96M | $193.24M | $81.61M | $122.22M |
| Long-term debt | $2.88M | $5.63M | $1.46M | $2.96M | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$131.08M | -$88.22M | -$53.55M | -$46.38M | -$34.11M |
| Capital expenditure | -$1.23M | -$2.21M | -$687.0K | -$2.45M | -$1.17M |
| Free cash flow | -$132.31M | -$90.43M | -$54.24M | -$48.83M | -$35.27M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CABA | $1.92 | -2.8% | 3.48M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |